Brogidirsen

N/A

Report date: 2026/03/07 20:00:27
NME

Base Information

Drug NameBrogidirsen
Drug Alias NameExon 44 skipping DMD therapeutic (Nippon Shinyaku)Exon 44 skipping antisense oligonucleotide (Nippon Shinyaku)NS-089/NCNP-02
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystrophin expression stimulants
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNippon Shinyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNs Pharma IncNippon Shinyaku Co Ltd
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A